title: Are selective estrogen receptor modulators (SERMs) a therapeutic option for HPV-associated cervical lesions and cancers?
abstract: This Commentary highlights the article by Spurgeon et al which evaluates oral SERM raloxifene as a potential therapeutic agent for HPV-associated cancer.
authors.affiliation: Division of Infectious Diseases, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address: kmunger@rics.bwh.harvard.edu.
authors.forename: Karl
authors.initials: K
authors.lastname: Munger
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D020845:Selective Estrogen Receptor Modulators